Could a single injection tame lupus and Sjögren's?

NCT ID NCT07751315

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This early-stage trial is evaluating an investigational drug called QLS2404, given as an injection, to see if it is safe and tolerable. The study first tests single doses in healthy volunteers, then moves to multiple doses in people with systemic lupus erythematosus or primary Sjögren's syndrome. Researchers will also look at how the drug moves through the body and whether it shows any signs of helping these autoimmune conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
QLS2404 injection
What this could lead to
If successful, this could point toward a new treatment option for autoimmune diseases like lupus and Sjögren's syndrome, potentially helping to control symptoms and reduce disease activity.
What could go wrong
This is an early-phase trial, so the main focus is safety, not effectiveness. The drug may not work as hoped, and side effects are possible. Results from this small study will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.